ITECH Trial Supportive of Ivermectin, Bio-Pharmaceutical Complex Launches War Against Generic Drug

Dr. McCullough appeared on Dan Ball's Real America after he posted a Tweet about the ITECH trial published from Malaysia in JAMA testing ivermectin in acute COVID-19. The trial was small and underpowered, but nevertheless there were numerically lower hard endpoints with IVM compared to placebo. There was been a war launched against the use of IVM by the Bio-Pharmaceutical Complex in it's attempt to push a vaccine-only strategy for the pandemic. Courtesy Real America February 23, 2022.

Citation:

Lim SCL, Hor CP, Tay KH, Mat Jelani A, Tan WH, Ker HB, Chow TS, Zaid M, Cheah WK, Lim HH, Khalid KE, Cheng JT, Mohd Unit H, An N, Nasruddin AB, Low LL, Khoo SWR, Loh JH, Zaidan NZ, Ab Wahab S, Song LH, Koh HM, King TL, Lai NM, Chidambaram SK, Peariasamy KM; I-TECH Study Group. Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Randomized Clinical Trial. JAMA Intern Med. 2022 Apr 1;182(4):426-435. doi: 10.1001/jamainternmed.2022.0189. Erratum in: JAMA Intern Med. 2022 Jun 01;182(6):690. doi: 10.1001/jamainternmed.2022.1523. PMID: 35179551; PMCID: PMC8980926.